Abbreviated name: CT (salmon)
Synonyms: Miacalcin®
calcitonin (salmon) is an approved drug (FDA (1978))
Compound class:
Peptide or derivative
Comment: A synthetic calcitonin receptor agonist. Salmon calcitonin has actions identical to calcitonins of mammalian origin, but its potency is greater and it is longer acting. The overall effect of calcitonin treatment is an increase in bone mass.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖View more information in the IUPHAR Pharmacology Education Project: calcitonin salmon |
No information available. |
Summary of Clinical Use |
Calcitonin (salmon) is used to treat hypercalcaemia of malignancy, osteitis deformans (Paget's disease of bone), for prevention of acute bone loss due to sudden immobility, and is used to treat postmenopausal osteoporosis in some countries. |
Mechanism Of Action and Pharmacodynamic Effects |
Calcitonin binds to the calcitonin receptor (found primarily in osteoclasts) and enhances the production of vitamin D producing enzymes. This results in increased calcium retention and enhanced osteogenesis and bone density. Binding of calcitonin to its receptor also activates the adenylyl cyclase and phosphatidyl-inositol-calcium signalling pathways |